[Pulmonary hypertension : What is new in therapy?]. / Pulmonale Hypertonie : Was ist neu in der Therapie?
Anaesthesist
; 65(8): 635-52, 2016 Aug.
Article
en De
| MEDLINE
| ID: mdl-27492004
ABSTRACT
Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Hipertensión Pulmonar
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
De
Año:
2016
Tipo del documento:
Article